2026年1月13日, 两名Apellis执行官不顾高收入出售股票, 股价为20.53美元。 
On January 13, 2026, two Apellis executives sold shares despite strong earnings, with stock at $20.53.
2026年1月13日, Apellis制药公司CFO Timothy Eugene Sullivan出售3 856股,每股22.19美元,David Watson总法律顾问以相同价格出售5 780股,这两笔交易都是向证交会申报的。 On January 13, 2026, Apellis Pharmaceuticals CFO Timothy Eugene Sullivan sold 3,856 shares at $22.19 each, and General Counsel David Watson sold 5,780 shares at the same price, both transactions filed with the SEC. 销售量将沙利文的股权降低了3.48%,华生的股权降低了5.52%。 The sales reduced Sullivan’s stake by 3.48% and Watson’s by 5.52%. 该公司报告说,2025年Q3收入强劲,EPS为1.67美元,收入增长133%,尽管分析家预测本年度损失1.7美元。 The company reported strong Q3 2025 earnings with $1.67 EPS and 133% revenue growth, though analysts project a $1.70 loss for the current year. 该股票于2026年1月15日以20.53美元关闭,市场上限为26亿美元,并获得一致的“稳住”评级。 The stock closed at $20.53 on January 15, 2026, with a market cap of $2.60 billion and a consensus “Hold” rating.
